【摘要】：當(dāng)前我國正處于向醫(yī)保支付價(jià)格為核心的藥價(jià)管理制度的轉(zhuǎn)型時(shí)期,本文對該制度框架內(nèi)國際基本模式之一的參考價(jià)格制度下代表性制藥強(qiáng)國的創(chuàng)新藥價(jià)管理進(jìn)行了國際比較。德、法、加這些典型國家新藥的定價(jià)和補(bǔ)償機(jī)制都具有定價(jià)與醫(yī)保支付掛鉤下的創(chuàng)新激勵(lì)與支付能力平衡,基于價(jià)值評價(jià)的分類等級管理,多種定價(jià)方式的綜合管理策略以及多元參與下的藥價(jià)決策機(jī)制等基本特點(diǎn)。這些為我國創(chuàng)新藥品管理的革新提供了重要啟示。
[Abstract]:At present, our country is in the transition period of the drug price management system with the core of paying the medical insurance price. This paper makes an international comparison on the innovative drug price management of the representative pharmaceutical power under the reference price system, one of the basic international models within the framework of the system. The pricing and compensation mechanisms of these typical new drugs in Germany, France and Canada all have the balance of innovation incentive and ability to pay under the linkage between pricing and medical insurance payment, and the classification level management based on value evaluation. The comprehensive management strategy of multiple pricing methods and the drug price decision-making mechanism under multi-participation. These provide important enlightenment for the innovation of drug management in our country.
【作者單位】： 南京中醫(yī)藥大學(xué)經(jīng)貿(mào)管理學(xué)院;
【基金】：國家中醫(yī)藥管理局中醫(yī)藥政策研究項(xiàng)目《中醫(yī)醫(yī)療服務(wù)價(jià)格政策體系研究》(ZYYP-2015);國家中醫(yī)藥管理局重點(diǎn)學(xué)科(中醫(yī)藥管理學(xué))開放課題項(xiàng)目《藥品支付基準(zhǔn)價(jià)格改革問題研究》(ZYYGLX-02)
【分類號】：R951

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 王雅楠;彭小宸;程s，

本文編號：2467245